Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies

Journal of Immunotherapy

Volumn 24, Issue 3, 2001, Pages 263-271

  Treon, Steven P ^a   Mitsiades, Constantine ^a   Mitsiades, Nicholas ^a   Young, Gloria ^a   Doss, Deborah ^a   Schlossman, Robert ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CD46; CD55; CD59; Complement; Drug resistance; Fas ligand; MUC1; Multiple myeloma; Rituximab; TRAIL; Waldenstrom macroglobulinemia

Indexed keywords

CD20 ANTIGEN; CD59 ANTIGEN; FAS LIGAND; MONOCLONAL ANTIBODY; MUCIN 1; RITUXIMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERODIAGNOSIS; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTIGENS, CD59; APOPTOSIS REGULATORY PROTEINS; B-LYMPHOCYTES; CA-15-3 ANTIGEN; FAS LIGAND PROTEIN; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MEMBRANE GLYCOPROTEINS; MICE; MULTIPLE MYELOMA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; WALDENSTROM MACROGLOBULINEMIA;

EID: 0034999619     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200105000-00011     Document Type: Article

References (43)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435.
2. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma. Blood 1997; 90:2188.
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825.
4. Byrd JC, Grever MR, Davis B, et al. Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a feasible and active regimen. Blood 1999, 94:704a.
5. Foran JM, Rohatiner AZS, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317.
6. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10:1525.
7. Weber DM, Gavino M, Huh Y, Cabanillas F, Alexanian R. Phenotypic and clinical evidence supports rituximab for Waldenstrom's macroglobulinemia. Blood 1999; 94:125a.
8. Treon SP, Shima Y, Prefer FI, et al. Treatment of plasma cell dyscrasias by antibody mediated immunotherapy. Semin Oncol 1999; 26:97.
9. Treon SP, Raje N, Anderson KC. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol 2000; 27:598-613.
10. Hussein MA, Karam MA, McLain DA, Elson P, Hsi E. Biologic and clinical evaluation of Rituxan in the management of newly diagnosed multiple myeloma patients. Blood 1999; 94:313a.
11. Weide R, Heymanns J, Koppler H. Induction of complete hematological remission after monotherapy with anti-CD20 monoclonal antibody (Rituximab) in a patient with alkylating agent resistant Waldenstrom's macroglobulinemia. Leuk Lymphoma 1999; 36:203.
12. Leo R, Boeker M, Peest D, et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol 1992; 64:132.
13. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63:1424.
14. Davis T, Levy R, White CA, et al. Rituximab: phase II retreatment study in patients with low-grade or follicular NHL. Blood 1998; 92:414a.
15. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10:655.
16. Multani PS, Grossbard ML. Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol 1998; 16:3691.
17. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80:863.
18. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9:995.
19. Schmitt CA, Schwaeble W, Wittig BM, Meyer zum Buschenfelde KH, Dippold WG. Expression and regulation by interferon-gamma of the membrane bound complement regulators CD46, CD55 and CD59 in gastrointestinal tumors. Eur J Cancer 1999; 35:117.
20. Bjorge L, Jensen TS, Matre R. Characterization of the complement regulatory proteins decay accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol Immunother 1996; 42:185.
21. Brasoveanu LI, Altomonte M, Gloghini A, et al. Expression of protectin (CD59) in human melanoma and its functional role in cell and complement mediated cytotoxicity. Int J Cancer 1995; 61:548.
22. Brasoveanu LI, Altomonte M, Fonsatti E, et al. Levels of cell membrane CD59 regulate the extent of complement mediated lysis of human melanoma cells. Lab Invest 1996; 74:33.
23. Varsano S, Rashkovsky L, Shapiro H, Radnay J. Cytokines modulate expression of cell membrane complement inhibitory proteins in human lung cancer cell lines. Am J Respir Cell Mol Biol 1998; 19:522.
24. Jarvis GA, Li J, Hakulinen J, et al. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 1997; 71:1049.
25. Villunger A, Egle A, Marchitz I, et al. Constitutive expression of Fas ligand on multiple myeloma cells: a potential mechanism of tumor induced suppression of immune surveillance. Blood 1997; 90:12.
26. Greil R, Egle A, Villunger A. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model. Leuk Lymphoma 1998; 31:477.
27. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998; 28:973.
28. Zhao S, Asgary Z, Wang Y, Goodwin R, Andreeff M, Younes A. Functional expression of TRAIL by lymphoid and myeloid tumor cells. Br J Haematol 1999; 106:827.
29. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999; 5:611.
30. Kinoshita T, Nagai H, Murate T, Saito H. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab. J Clin Oncol 1998; 16:3916.
31. Schmitz K, Brugger W, Weiss B, Kaiserling E, Kanz L. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol 1999; 106:571.
32. Maloney D, Smith B, Appelbaum F. The anti-tumor effect of monoclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkins lymphoma (NHL) cell lines. Blood 1996; 88:637a.
33. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B-cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91:1644.
34. Mathas S, Bommert K, Dorken B, Mapar MY. Anti-CD20 antibody mediated apoptosis is dependent on caspase 3 activation. Blood 1998; 92:405a.
35. Morgan BP, Harris CL. Complement Regulatory Proteins. London: Academic Press, 1999.
36. Bjorge L, Matre R. Downregulation of CD59 (Protectin) expression on human colorectal adenocarcinoma cell lines by levamisole. Scand J Immunol 1995; 42:512.
37. Treon SP, Mollick JA, Urashima M, et al. MUC1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 1999; 93:1287.
38. Treon SP, Teoh G, Urashima M, et al. Anti-estrogens induce apoptosis of multiple myeloma cells. Blood 1998; 92:1749.
39. Patton S, Gendler SJ, Spicer AP. The epithelial mucin, Muc1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1995; 1241:407.
40. Golay J, Zaffaroni L, Vaccari T, et al. Biological response of B lymphoma cell lines to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated lysis. Blood 2000; 95:3900.
41. Matsuo S, Ichida S, Takizawa H, et al. In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J Exp Med 1994; 180:1619.
42. Bergenbrant S, Osterborg A, Holm G, Mellstedt H, Lefvert AK. Anti-idiotypic antibodies in patients with monoclonal gammopathies: relation to the tumor load. Br J Haematol 1991; 78:66.
43. Wen YJ, Ling M, Barlogie B, Lim SH. Isolation and characterization of human myeloma antigens recognized by autologous IgG antibodies. Blood 1999; 94:118a.